Cystic Fibrosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995

This report deliverables include a PowerPoint report and an Excel-based forecast model and covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada). The base year of the sales forecast model is 2024, and the forecast period is 2024-2034. This report also includes a number of recent enhancement to the forecast models, specifically the US LoA analysis tab and the interactive patient flow tab. The patient flow tab helps to summarize the number of patients treated on each class of therapy for each year of the forecast period for the 7MM.

GlobalData estimates that throughout the forecast period (2024-2034), 12-month diagnosed prevalent cases of cystic fibrosis (CF) are anticipated to increase in the 7MM, across all age-groups. Treatment rates will also increase because of roll-out of more newborn screening and genetic testing programs, improved life expectancy of patients, and anticipated increase in treatment options with the launch of novel CFTR modulators and pipeline agents. The CF pipeline in the 7MM remains limited with most of the pipeline targeting the CFTR, suggesting a shift from symptom management to disease targeting. The CF market is expected to grow from $11.1 billion in 2024 to $16.0 billion by 2034 at a compound annual growth rate (CAGR) of 3.8% across the 7MM.

Scope

Overview of cystic fibrosis (CF) – including epidemiology, disease etiology and management.

Topline CF drugs market revenue, annual cost of therapy, and anticipated sales for late-stage pipeline drugs.​

Key topics covered include assessment of marketed therapies and pipeline agents, unmet needs, pipeline assessment and market outlook for the US, 5EU, and Canada over the 10-year forecast period.​

Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.​

Analysis of the current and future market competition in the seven-market CF therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.​

Develop business strategies by understanding the trends shaping and driving the seven-market cystic fibrosis (CF) therapeutics market.​

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market CF market in the future.​

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.​

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.​

Track drug sales in the seven-market CF therapeutics market from 2024-2034.​

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Vertex Pharmaceuticals
Roche
Merck
Verona Pharma
4D Molecular Therapeutics
BiomX
Novabiotics
Enterprise Therapeutics
Spirovant Sciences
Boehringer Ingelheim
Armata Pharmaceuticals
Arna Pharma

Table of Contents

PowerPoint Deck

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Disease Overview

3.1. Overview of Cystic Fibrosis

3.2. Etiology and Pathophysiology of Cystic Fibrosis

3.3. Classification of Cystic Fibrosis

3.4. Cystic Fibrosis SWOT Analysis

4. Epidemiology

4.1. Registry-Based Diagnosed Prevalent Cases of Cystic Fibrosis, N, Men and Women, 2024─34

4.2. Registry-Based Diagnosed Prevalent Cases by Age, N, Men and Women, All Ages, 2024

4.3. Registry-Based Diagnosed Prevalent Cases by Sex, N, Men and Women, All Ages, 2024

4.4. Registry-Based Diagnosed Prevalent Cases by Mutation, N, Men and Women, All Ages, 2024

4.5. Registry-Based Diagnosed Prevalent Cases by Mutation, N, Men and Women, All Ages, 2024

4.6. Registry-Based Diagnosed Prevalent Cases with MRSA Infection, N, Men and Women, All Ages, 2024

4.7. Adjusted Diagnosed Prevalent Cases of Cystic Fibrosis, N, Men and Women, 2024─34

4.8. Adjusted Diagnosed Prevalent Cases by Age, N, Men and Women, All Ages, 2024

4.9. Adjusted Diagnosed Prevalent Cases by Sex, N, Men and Women, All Ages, 2024

4.10. Adjusted Diagnosed Prevalent Cases by Mutation, N, Men and Women, All Ages, 2024

4.11. Adjusted Diagnosed Prevalent Cases with MRSA Infection, N, Men and Women, All Ages, 2024

4.12. Sources and Methodology for Registry-Based Diagnosed Prevalent Cases of Cystic Fibrosis

4.13. Sources and Methodology for Registry-Based Diagnosed Prevalent Cases of Cystic Fibrosis with MRSA Infection

4.14. Sources and Methodology for Adjusted Diagnosed Prevalent Cases of Cystic Fibrosis

4.15. Sources and Methodology for Diagnosed Prevalent Cases of Cystic Fibrosis by Mutation

4.16. Sources and Methodology – Registry-Based Diagnosed Prevalence of Cystic Fibrosis

4.17. Sources and Methodology – Adjusted Diagnosed Prevalence of Cystic Fibrosis

4.18. Sources and Methodology – Diagnosed Prevalence of Cystic Fibrosis by Mutation

4.19. Sources and Methodology – Diagnosed Prevalence of Cystic Fibrosis by MRSA Infection

5. Current Treatment Options

5.1. Treatment Paradigm

5.2. Current Treatment Options

5.3. Product Profile: Vertex Pharmaceuticals’ Kalydeco (ivacaftor)

5.4. Product Profile: Vertex Pharmaceuticals’ Orkambi (ivacaftor + lumacaftor)

5.5. Product Profile: Vertex Pharmaceuticals’ Symdeko/Symkevi (tezacaftor + ivacaftor and ivacaftor)

5.6. Product Profile: Vertex Pharmaceuticals’ Trikafta/Kaftrio (elexacaftor + tezacaftor + ivacaftor and ivacaftor)

5.7. Product Profile: Vertex Pharmaceuticals’ Alyftrek (deutivacaftor + tezacaftor + vanzacaftor calcium)

5.8. Product Profile: PERTs (Creon, Pancreaze, Pertzye, UltresaTM, and Zenpep)

5.9. Product Profile: Inhaled Antibiotics (tobramycin, aztreonam)

5.10. Product Profile: Roche’s Pulmozyme (dornase alfa)

5.11. Product Profile: Arna Pharma’s Bronchitol (mannitol)

5.12. Product Profile: Anti-Inflammatory Therapies (azithromycin, ibuprofen)

6. Patient Flow

6.1. Patient Flow: CF in 2024 Across the 7MM

7. Unmet Needs and Opportunities

7.1. Curative and Broader-Acting Therapies

7.2. Therapies for Chronic Lung Infection

7.3. Novel Mucolytic Therapies

7.4. Improvement of Treatment Compliance

8. R&D Strategies

8.1. Trends in Clinical Trials Design and Clinical Development

8.2. Trends in Deal-Making in Cystic Fibrosis

9. Pipeline Assessment

9.1. CF Pipeline Overview

9.2. Late-Stage Pipeline Agents for CF

9.3. Product Profile: 4D Molecular Therapeutics’ 4D-710

9.4. Product Profile: BiomX’s BX-004

9.5. Product Profile: Novabiotics’ Cysteamine/NM001/Lynovex

9.6. CF: Clinical Trials (Phase II/III) Overview

10. Market Outlook

10.1. CF Market Forecast

10.2. Market Drivers and Barriers

11. Appendix

11.1. Primary Research: KOL Information

11.2. Bibliography

11.3. About the Authors

12. Contact Us

Cystic Fibrosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cystic Fibrosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 in real time.

  • Access a live Cystic Fibrosis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.